Conclusions: Natural and treatment-induced substitutions in HBV core protein, occurring especially with interferon treatment, were characterized. Some immunestimulating activity related to the minor Th28-47 epitope might be associated with nucleoside/nucleotide analogues; this activity was also seen in inactive carriers.
The HBV DNA core region encodes the hepatitis B core antigen (HBcAg), the viral capsid component and hepatitis B e antigen (HBeAg), a secreted nonparticulate form of HBcAg [1, 2] . HBV is not directly cytopathic; the cellular immune response is believed to be responsible for the pathogenesis of the disease. Infected hepatocytes are recognized and destroyed by HBV-specific cytotoxic T-lymphocytes, which act against peptides bound to human leukocyte antigen (HLA) type-I that is expressed on the cell surface [3, 4] . Resolution of acute HBV infection is associated with a multispecific CD4 + T-helper and CD8 + cytotoxic T-lymphocyte response [5] . Development of chronic hepatitis B (CHB) infection is associated with poor establishment of the immune response during the acute phase [4, 6] .
HBeAg and HBcAg, which share a large number of amino acids (AA) and some epitopes for B-and T-cells, are important targets for antiviral immunity [7] [8] [9] . HBcAg, which is more immunogenic than hepatitis B surface antigen (HBsAg) and HBeAg proteins, is a major target for immune-mediated viral clearance, inducing B-cell, T-helper and cytotoxic T-lymphocyte responses. The nucleocapsid-specific CD4 + T-cell response has been identified as the dominant helper response correlating with recovery of HBV infection [4, [10] [11] [12] . Several epitopes have been identified in HBcAg [11] . An important one is the immunodominant CD4 + T-helper
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Maria Homs 1, 2 , Rosendo Jardi 1, 2 , Maria Buti 1, 3 , Melanie Schaper 1, 2 , David Tabernero 1, 2 , Pilar Fernandez-Fernandez 2 , Josep Quer 1, 3 , Rafael Esteban 1, 3 , Francisco Rodriguez-Frias 1, 2 Introduction epitope unrelated to HLA haplotype, which is located between AA 50 and 69 (Th50-69) [13] . The major antibody specificities against HBcAg lie on the outside of the capsid structure, particularly at the tip of spikes where the main core antigenic loop is located, including the immunodominant B-cell epitope between AA 74 and 84 (B74-84) [9, 14, 15] . Although HBcAg contains a large percentage of invariant AA, significant sequence diversity is seen, predominantly in the capsid spikes where the two immunodominant epitopes are located [15] . This variability might cause alterations in the immunogenic core epitopes by modifying their sequences, which would decrease HBV recognition by T-cells and result in a low antiviral immune response, or even immune escape [4, 16, 17] . HBcAg AA changes have been associated with viral persistence by influencing the host immune response and the natural course of HBV infection [2, 9, 18, 19] . These changes mainly occur in immunodominant T-and B-cell epitopes, such as Th50-69 and B74-84 [10, 11, 16, 19] . The primary goal of antiviral treatment for CHB infection is sustained suppression of HBV replication and remission of liver disease. The antiviral effect of interferon (IFN) is mainly based on enhancing the cellular immune response against infected hepatocytes by increasing expression of major histocompatibility class I antigens and stimulating the activity of T-helper cells and natural killer lymphocytes [11] . Selection of HBcAg changes caused by IFN pressure or during natural seroconversion mainly occurs in immunodominant T-and B-cell epitopes recognized by CD4 + T-helper cells or by B-cells, and is considered an immune escape mechanism [12, 16, 19] . A large number of nucleoside/nucleotide analogues that act as HBV reverse transcriptase inhibitors are currently available to treat CHB [20] . To date, there are no studies investigating the relationship between emergence of AA changes in HBcAg epitopic regions and nucleoside/nucleotide analogue treatment.
The aim of this study was to evaluate a selection of HBV core gene changes in three epitopic regions ( Figure 1 ): the main CD4 + T-cell recognition site (Th50-69), the main B-cell site (B74-84) [13, 21, 22] and a minor T-helper cell recognition site between AA 28 and 47 (Th28-47) [21] [22] [23] . In addition, we examined a conserved region of HBcAg from AA position 1-11 (AA1-11) [15] . These core regions were analysed in CHB patients with persistent viral activity and in inactive HBsAg-positive carriers. In CHB patients, selection of changes in the core nucleotide sequence was examined at baseline and in several additional serum samples: after a treatment-free period, and after non-response to IFN, lamivudine (3TC) or adefovir dipivoxil (ADV) therapy. The role of the G1896A HBV precore variant and HBV genotypes in selecting HBV core changes was also analysed.
Methods

Patients
A retrospective study was carried out in 76 CHB patients diagnosed and followed-up in our centre (Vall d'Hebron Hospital, Barcelona, Spain). In addition, a group of 20 inactive HBsAg-positive carriers were analysed for inclusion in the study. Inactive carriers were defined as follows: HBsAg-positive, detection of antibody against HBeAg (anti-HBe), normal alanine aminotransferase levels and low rates of viral replication (HBV DNA≤4 log 10 copies/ml) over the entire duration of known infection. Because of the study requirement to analyse two samples at different time points, only four inactive carriers who had HBV DNA levels between 3 and 4 log 10 copies/ml after 12 months were included in the study.
A total of 185 serum samples from the 80 patients enrolled in the study were analysed. These included a baseline serum sample from the 76 CHB patients and serial samples corresponding to various time points, which were classified as the treatment-free period group, the IFN, 3TC and ADV treatment period groups, and the inactive carrier group.
To evaluate the natural evolution of the HBV viral quasispecies, 23 of the 76 CHB patients, all of whom had remained untreated during a period of at least 12 months, were selected. Samples obtained after this treatment-free period (that is, before any treatment was initiated) were analysed as a separate group. In total, 21 of these patients were later treated with one of the study drugs, and samples from these patients at the time of non-response to therapy were included in the patient samples for the various treatment groups.
Overall, 64 patients had received treatment or were under treatment, as sequential monotherapies in all cases. A total of 35 patients were HBeAg-positive, and 6 (17%) of them had a total loss of HBeAg during 3TC therapy. Both the HBeAg-positive and -negative patients had documented CHB and persistent HBV DNA serum levels ≥4 log 10 copies/ml over the entire study period. The 22 patients treated with IFN had been selected because all were non-responders to this therapy. Although all of these patients received various therapies after IFN, the subsequent treatments were analysed in only 5 cases; the remaining 17 patients were analysed only after IFN treatment. A total of 26 patients received only 3TC, and 8 were treated only with ADV. Another 13 patients were sequentially treated: 4 treated with IFN followed by 3TC, 1 treated with IFN followed first by 3TC and then by ADV, and 8 treated with 3TC followed by ADV. Thus, a total of 22 treatment periods corresponding to the IFN period, 39 corresponding to 3TC and 17 corresponding to ADV were analysed. The serum sample for the IFN treatment group was taken 6 months after starting therapy, and the samples for 3TC and ADV were drawn at ≥12 months after starting therapy or when a lack of response was evident. IFNtreated patients received IFN-α2b (Intron-A ® ScheringPlough, Kenilworth, NJ, USA) at 5 million units/day for 24 weeks or pegylated IFN (PegIntron ® ; ScheringPlough) at 180 µg/week for 24 weeks, depending on the year when therapy started. Patients with nucleoside/ nucleotide analogues were treated with 3TC 100 mg/ day (Zeffix ® ; Glaxo Wellcome UK, Ltd, Uxbridge, UK) or ADV 10 mg/day (Hepsera ® ; Gilead Laboratories, Foster City, CA, USA). The main demographic, biochemical, virological and histological data of the study patients are shown in Table 1 .
HBV core region analyses
Four HBV core regions were analysed longitudinally. These included three epitopic regions of HBcAg, Th28-47, Th50-69 and B74-84 [12, 13, [20] [21] [22] [23] , and the conserved region, AA1-11, in the N-terminal region of HBcAg [15] (Figure 1) . A total of 185 serum samples were studied. Baseline sequences were compared with consensus sequences established for each genotype by alignment of 185 complete GenBank sequences of HBV genotypes A to H. Only sequences obtained from the genotypes identified in the study patients (A, D and F) were used in this analysis. Sequences obtained at the beginning and at the end of each study condition period in each patient (treatment-free, following IFN, 3TC or ADV treatment, and inactive carriers) were compared.
To enable proper comparisons, the average number of AA changes in each region and study condition period were standardized to 12 months (Av12) as follows: number of AA changes divided by months in the period and multiplied by 12. For the baseline sequences, the known time of infection to baseline was used in the Av12 calculation. The standardized results were also averaged for each group. Baseline samples and the 12-month treatment-free samples were used as a measure of the natural evolution of the virus. The rationale for this standardization step was based on the knowledge that viral evolution is a time-dependent process, and in this way more comparable results could be obtained. For example, an observation of 3 changes in 6 months is not the same as 3 changes in 12 months, and patients were treated for different periods of time. The selected patients receiving IFN were treated for only 6 months (as was recommended at that time), whereas samples from the remaining patients were collected at ≥12 months. Standardization to 12 months was done to enable observation of AA substitutions even in periods when less variation was expected (for example, in the treatment-free periods) and in the most conserved regions. The Av12 changes were statistically analysed for each region and study condition period (treatment-free, following IFN, 3TC or ADV treatment, and inactive carriers). Results are expressed as the mean and range.
Serological and virological testing
HBsAg, HBeAg and anti-HBe were determined by EIA (Ortho Clinical Diagnostics, Amersham, Buckinghamshire, UK). HBV copy number was quantified by realtime PCR using the LightCycler system (Roche Diagnostics, Mannheim, Germany) with a detection limit of 5×10
2 copies/ml, as previously described [24] . HBV genotyping was performed by sequence alignment, as previously described [25] .
Amplification and sequencing of the HBV core region HBV DNA was extracted from serum by QIAamp microspin columns (QIAamp DNA Mini Kit, Quiagen, Hilden, Germany), according to the manufacturer's instructions. A 760 bp DNA fragment of HBV, located in the precore-core region of the HBV genome, was amplified by nested PCR using specific primers. First PCR: sense primer, nucleotides 1662-1681;
5′-(C/T)ATAAGAGGACTCTTGGACT-3′ Liver biopsy performed during the period.
c Six (17%) cases lost hepatitis B e antigen (HBeAg) after lamivudine (3TC) treatment. ADV, adefovir dipivoxil; ALT, alanine aminotransferase; CAH, chronic active hepatitis; CHB, chronic hepatitis B; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; IC, inactive carrier; IFN, interferon; LC, liver cirrhosis; MT, mutated form of main precore mutation (A1896); PC, precore region; WT, wild-type form of main precore mutation (G1896); WT/MT, detection of both wild-type and mutation in main precore mutation (G/A1896); TF, treatment-free period.
and anti-sense primer, nucleotides 2912-2931; 5 ′-TGTTCCCA(A/G)GAATA(A/T)GGTGA-3′. Nested PCR: sense primer, nucleotides 1800-1822; 5′-CCC(A/C)GTAAA(A/G)TT(C/T)CCCACCT-TAT-3′ and anti-sense primer, nucleotides 2540-2559; 5′-GGCTGTAGGCATAAATTGGT-3′. This fragment includes nucleotide 1896 of the precore region, in which a change from G to A abolishes HBeAg expression.
Sequencing was performed with the Big Dye Terminator version 1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and nested primers. Products were analysed with the ABI Prism 310 automatic genome analyzer (Applied Biosystems) and the consensus sequence of each patient was obtained.
Statistical analyses
Comparisons between quantitative variables were performed using the Student's t-test or Mann-Whitney U test (between groups), and the Wilcoxon signed-rank test (within group). Qualitative variables were compared with the Fisher's exact test and McNemar's test. Differences were considered statistically significant at P-values of <0.05. We also examined the possible significance of HBV genotypes and mutant forms of the precore region. All statistical analyses were performed with SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, USA)
Results
A total of 185 sequences were processed. The changes observed in each codon of the four core regions of the six groups analysed (baseline, treatment-free, after IFN, 3TC, or ADV, and inactive HBsAg-positive carriers) were standardized to 12 months (Av12). After standardizing, the mean number of changes in the four regions studied for each group was calculated, with the following results: 3.4 in the CHB baseline samples, 1.5 in the treatment-free period, 7.6 after IFN treatment, 2.3 after 3TC treatment, 3.2 after ADV treatment and 3.5 in inactive carrier patients ( Figure 2 ).
AA analyses in baseline serum samples
Sequences from the 76 CHB patients obtained at baseline were analysed to assess the prevalence of AA substitutions in the three epitopic regions and conserved AA1-11 region. AA changes were compared with consensus sequences, relative to the known time of infection. The percentages of CHB cases with changes in epitopic regions (37% Th28-47, 55% Th50-69 and 59% B74-84) were higher than the percentage in the conserved region (9% AA1-11; P<0.001; Figure 3A ). The Av12 changes were also lower in AA1-11 than in the three epitopic regions (P<0.001), with the minor Th28-47 region being less variable than the two immunodominant epitopes (P<0.001; Figure 3B ). Six of the seven most variable codons (Av12≥0.1) were clustered in the immunodominant epitopes ( Figure 2 
AA changes and their relationships with absence of treatment, antiviral therapy and inactive HBsAg carrier status
The 64 treated CHB patients (including 22 IFN-treated, 39 3TC-treated and 17 ADV-treated samples), 23 treatment-free period samples, and 4 inactive HBsAgpositive carriers were included in this analysis. Baseline and treatment-free samples were used to examine the natural evolution (that is, without drug administration) of the viral quasispecies during CHB infection. Percentages of cases with changes and statistical significance in the comparisons between groups and regions are shown in Figure 3A . In a significant percentage of treatment-free samples, changes were selected in the epitopic regions, mainly in the two immunodominant ones (52% in Th50-69 and 56% in B74-84), at values similar to those observed at baseline and after 3TC or ADV treatment, but lower than those recorded after IFN therapy (72% in Th50-69 and 86% in B74-84). Statistical differences between treatment-free and IFN cases were only found in B74-84 (P=0.04); however, the percentage of changes in the minor epitope Th28-47 was higher after 3TC and ADV (36% for 3TC and 47% for ADV) than in the treatment-free group (9%; P=0.03 and P=0.01, respectively). Percentages of changes in B74-84 were significantly higher after IFN therapy than after 3TC or ADV (P=0.01 and P=0.03, respectively).
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When the three antiviral therapies were compared (Figure 3B) , the Av12 was higher in the immunodominant Th50-69 and B74-84 epitopes following IFN than after 3TC or ADV therapy (P<0.05). Similar results were found when the IFN group was compared to the treatment-free group (P=0.001). After ADV treatment, the Av12 was significantly increased in the minor immunodominant Th28-47 region in comparison with the treatment-free samples (P=0.04; Figure 3B ). In the comparison between inactive carriers and CHB patients, differences approaching significance were found in the immunodominant regions Th50-69 (P=0.05) and B74-84 (P=0.06) between samples corresponding to IFN therapy, and in the Th28-47 region only in the treatment-free samples (P=0.06). A total of 9 of the 23 treatment-free patients presented reactivation episodes; however, no significant differences were found in the pattern or number of AA changes relative to patients in whom reactivations were not observed.
Patient-by-patient comparison of AA changes between the treatment-free period and following IFN regions was performed in 16 patients who were treatment-free for ≥12 months before starting IFN. The substitutions observed in the absence of treatment were compared with those detected after IFN therapy ( Figure 4) . As was seen in the overall longitudinal study, this analysis showed significant differences in the Av12 number of AA changes between the IFN-treated and treatment-free period in the Th50-69 (P=0.002) and B74-84 (P=0.01) epitopes. Differences were also significant relative to baseline (P=0.005 for Th50-69 and P=0.04 for B74-84).
Most common AA changes and their relationships with absence of treatment, antiviral therapy and inactive HBsAg carrier status
In the total population, eleven codons showed ≥10 absolute AA substitutions. The distribution of these changes and their stability in the various study conditions are shown in Table 2 . More than one type of substitution was observed in each position, with codon 74 being particularly polymorphic (V/N mainly changed to A but also to D, K, H or I). The largest numbers of substitutions were in codon 77, with 36 changes, and codon 74, with 33 changes. A total of 31 of the 87 substitutions observed in these positions at baseline were seen to persist after the various study periods (three after the treatment-free period, IFN, and lastly, 3TC therapy). In the sequential study, 103 AA changes were selected: 16 (mean 0.8) after the treatment-free period, 10 of which remained after treatment (the N74A change was stable after IFN, 3TC and ADV therapy), 29 (mean 1.3) after IFN, 36 (mean 0.9) after 3TC and 22 (mean 1.3) after ADV.
The most prevalent AA substitutions in CHB patients were 24 E77Q, 13 N/V74A and 13 E64D; T67N was also observed in 6 (46%) of the patients with E64D changes. In 15 positions in the regions analysed, the differences in Av12 values between groups were significant or approached significance (Table 3) . Interestingly, no differences in the highly variable codon 74 were observed. All positions in which Av12 changes were higher after IFN therapy than in the other study conditions were located in the main epitopic regions, Th50-69 and B74-84. Of note, the Av12 value for codon 84 (substitutions L84Q/R/H) was higher after IFN therapy (Av12=0.46) than in the other groups. Nucleotide substitutions that were significantly more common after ADV therapy than in the other groups were mainly located in the minor Th28-47 epitope (codons 38, 41, 45 and 46), or in the conserved AA1-11 region (codon 3 and 4). Only one position in the main epitopic regions (codon 51) was more variable following ADV (Av12=0.29) than 3TC (no changes; P=0.04). Changes in position 59 were the only ones found to be more common after 3TC than after the treatment-free period (P=0.05). 
Discussion
An increase in the number of AA substitutions in HBcAg during chronic HBV disease has been described, mainly clustering in the CD4 + , CD8
+ and B-cell immunodominant epitopes [17, 18] . Although these variants are associated with persistence of chronic infection and sensitivity to IFN therapy, their real significance remains controversial [7, 17, 21, 23, [26] [27] [28] , and their distribution does not show specific patterns [3, 18] . The present study investigated the natural occurrence and selection of HBV core variants in treatment-free CHB patients and those under treatment (IFN, 3TC or ADV) as the external evolutionary factor. The effect of IFN has been reported previously [17, 24, 29] , but there are no studies investigating core variants in patients receiving nucleoside/nucleotide analogues. In the present study, HBV core substitutions were examined while active viral replication was occurring. Hence, possible associations of core nucleotide changes with response to antiviral therapy were not determined.
The study focused on three epitopic regions, including immunodominant Th50-69 and B74-84, and minor Th28-47, as well as the AA1-11 region. The Th18-27 epitope [30, 31] , which is also located in the 760 bp precore-core region analysed, was not studied because of the small number of changes detected (only seven cases; MH et al., data not shown). The baseline analysis detected a high prevalence of HBV core variants, particularly in the immunodominant regions (>50% of cases), concurring with previous reports showing a high rate of core substitutions in HBeAg-negative cases, mainly in the Th50-69 region [16, 25, 28, 29, 32] , and in cases with the main precore variant [18, 23, 27] . b Time in months. BL, sample obtained at baseline; Gen, HBV genotype; HBe, hepatitis B e antigen; IFN, sample obtained after 6 months of interferon treatment; MT, presence of main precore mutation; N, negative; P, positive; PC, main precore mutation (G1896) status; TF, sample obtained after the treatment-free period; WT, absence of main precore mutation; WT/MT, detection of both wild-type and mutation in main precore mutation. Wild type  Y38  E40  H51  H52  I59  E64  M66  N/V74  E77  P79 Baseline  4  9  3  2  4  7  2  9  7  6  3  TF  ------1  2  -1  2  IFN  1  1  2  2  2  3  2  3  5  1  5  3TC  2  1  -1  2  4  2  7  8  -3  ADV  3  3  5  1  ---4  4 2 -Changes retained during consecutive periods Total changes  CHB  11  21  11  10  12  17  10  32  34  14  18  IC  -3  ---1  1  1  2  -1   Table 2 . Amino acid positions with the highest variability observed in this study a For each position the wild-type form is shown and all substitutions are indicated in the row showing change; the underlined amino acid indicates the most frequent change (for example, for E77Q/N/K, the most frequent change is E77Q).
Changes detected in one period
b Baseline-3TC - 2 - - 3 2 1 3 3 3 2 Baseline-TF - - - - - - - - 2 - - Baseline-TF-IFN 1 2 - - - - 1 1 - - 1 Baseline-TF-IFN-3TC - - - 1 - - 1 - - - 1 Baseline-TF-3TC - - - - - - - - - 1 - TF-IFN - - 1 1 - 1 - - 2 - 1 TF-IFN-3TC-ADV - - - - - - - 1 - - - TF-3TC - 1 - 1 - - - - 1 - - IFN-3TC - - - 1 - - - - 1 - - 3TC-ADV - 2 - - 1 - - 2 1 - -
b
Changes were detected in the first period indicated in the row of the first column and retained through the consecutive periods. For example, two E40D changes were observed at baseline and remained in the treatment-free period (TF) and the period under interferon (IFN) treatment (cases 13 and 15 in Figure 3) , and one N74A change was selected during TF and remained after subsequent IFN, lamivudine (3TC) and adefovir dipivoxil (ADV) treatments (case 4 in Figure 3) . CHB, chronic hepatitis B; IC, inactive carrier. All these findings suggest enhanced immune pressure against core epitopes by HBeAg loss, which we will discuss later. Interestingly, HBV DNA levels were higher in patients with AA changes in B74-84 than in those without, in keeping with the findings of other authors [32, 33] , but contrasting with a recent study by Sendi et al. [31] , in which AA substitutions were more frequent at low HBV DNA levels, as well as in inactive HBsAg-positive carriers. We suggest that the presence of core AA changes enables HBV to evade immune clearance, thereby lengthening the life of the infected hepatocyte and increasing the viral population. This would provide the possibility of infecting more hepatocytes and ultimately raise the serum HBV DNA level, as occurred in our patients. The natural evolution of the HBV core gene, evaluated in treatment-free serum samples, yielded the highest variability in the immunodominant epitopes and greatest conservation of the AA1-11 region, as has been described previously [15] . Interestingly, the percentage of changes in AA1-11, Th28-47 and B74-84 observed in the inactive carrier group was higher than in untreated CHB patients, in accordance with a recent report [31] . AA substitutions in epitopic regions in both untreated and inactive patients indicate persistent immune activity and suggest a viral escape mechanism [16, 17, 28] , but the host response seems to differ in these two patient populations. Nonetheless, because of the small number of inactive carriers included in this study, these results should be interpreted with caution.
Regarding the effect of antiviral therapy on core gene evolution, we found a tendency to conserve the AA1-11 region, although variability was slightly higher than at baseline and in treatment-free periods. The percentage of changes in the immunodominant Th50-69 and B74-84 epitopes was higher after IFN therapy than in the remaining treated groups, in keeping with the expected immune-stimulating effect of IFN [34] . Core substitution selection during IFN therapy has been reported previously [17, 24, 29] ; however, in the present study, we compared IFN-treated and treatment-free periods, as well as the treatment-free and IFN-treated period in each patient for whom the two measures were available. In both analyses, immunodominant regions under IFN stimulus showed higher variability than the other combinations of regions and conditions studied.
An increase in spontaneous or IFN-induced HBV core sequence diversity has also been reported after HBeAg seroconversion [28] . Among our IFN-treated patients, 80% were anti-HBe-positive; thus, the high rate of AA changes in core immunodominant epitopes observed after IFN therapy is consistent with these reported results. Apparently, changes selected under IFN can evade detection and elimination by the immune system, thereby allowing HBV escape and maintaining active infection. We found no differences in the rate of AA changes between HBeAg-positive and anti-HBepositive patients after IFN treatment, in contrast to the findings of Lim et al. [28] . This discrepancy might be related to the differing ethnic origin, viral genotypes, small number of seroconverters and the fact that only non-responders were included in our study.
The antiviral effect of nucleoside/nucleotide analogues is based on inhibition of viral replication by targeting HBV reverse transcriptase activity. No immunomodulator activity has been described. Thus, similar results in immunodominant epitopes were expected between untreated patients and those treated with 3TC or ADV. Surprisingly, minor Th28-47 epitope variability after nucleoside/nucleotide analogue treatment was higher than in the treatment-free period, suggesting stimulation of T-helper CD4 + activity against this epitope. A possible explanation for these results might be related to the effect of nucleoside/nucleotide analogue antiviral treatment, which decreases retrotranscriptase activity, but not pregenomic HBV RNA production or viral antigen expression. This could result in an accumulation of immature core particles, which might stimulate the proteosome, increasing production of viral epitopes and their expression on the hepatocyte membrane, and ultimately increasing immune pressure against these cells. We suggest that changes detected in Th28-47 of the core region are selected during nucleoside/nucleotide analogue treatment and could confer an escape mechanism from immune pressure; however, the reason why this theoretical phenomenon was more evident in Th28-47 than in the immunodominant epitopes remains unexplained.
HBcAg and HBeAg are highly cross-reactive at the T-cell level: the immunodominant loop, which includes the B74-84 epitope, is involved in the antigenicity of both of these proteins [9] . It is known that HBeAg can contribute to the outcome and pathogenesis of HBV infection, inducing tolerance in HBcAg-specific T-cells and reducing their potential to kill HBV-infected cells [35] . In this regard, HBeAg upregulates toll-like receptor expression in CD4 + CD25 + T-regulatory cells, an action associated with inhibition of the T-cell response [36, 37] . This factor, and the existence of cross-reactive HBeAg/HBcAg epitopes would facilitate viral persistence [38] . It can be hypothesized that after the main precore variant selection (G1896A), the HBeAg immune-tolerant effect is lost and HBcAg epitopes expressed on the hepatocyte surface come under the pressure of the immune system. Thus, a higher number of HBV core substitutions would be detected in patients with a precore variant, as was seen at baseline and reported previously [18, 23, 27] ; however, these results were not observed in the sequential analysis of the treatment-free, IFN and ADV periods.
Moreover and surprisingly, after 3TC therapy, the numbers of AA substitutions in the immunodominant Th50-69 and B74-84 regions were higher in wildtype cases than in precore mutant cases. Our findings could explain the reported cases of reselection of wildtype sequences after 3TC therapy [39] as the result of preferential immunoselection of precore wild-type sequences because they have a higher number of core substitutions than sequences with precore variants.
After IFN therapy, the most frequent AA substitutions were in the immunodominant regions, whereas after ADV, they were similarly distributed between immunodominant and minor Th28-47 regions. Also, specific changes in the minor Th28-47 epitope (codons 41, 45 and 46) were seen more often after ADV therapy than in the treatment-free period. Both these findings suggest differential immune stimulation during ADV therapy, more specifically associated with this minor epitope. Despite the finding that the substitution patterns detected were not specific, some changes were especially interesting. The E64D substitution in the Th50-69 region is notable, being observed in all the periods analysed except after ADV therapy. This change significantly reduces T-cell proliferation in vitro when linked to T67N, altering the E 64 LMT 67 sequence, a common motif in T-cell epitopes [16] ; thus, it is selected by the effect of immune pressure. In our patients, the double E64D-N67T change was observed in 46% of patients with an E64D substitution.
The main variants observed in the B74-84 region over the entire study were N74A/D and E77Q, which were similarly distributed between the baseline and sequential groups, indicating that their selection was not the result of specific evolutive pressures. Both codons are highly polymorphic [15] , and their variants are often detected in CHB and inactive carrier cases [17, 19, 23, 29, 40] ; however, changes in codon 77 have been associated with the HLA-B*4001 allele [41] and might be involved in viral escape mechanisms. Large studies are needed to determine the effect of these variants on immunological reactivity against HBV.
Interestingly, in the present report, selection of changes in codon 84 (mainly L84Q) was associated with IFN therapy. Although highly polymorphic positions, such as 74, 77 and 84 [15] have been observed with IFN therapy [17, 29] , there are no studies investigating their status after other therapies or the absence of treatment.
Despite the small number of HbsAg-positive inactive carriers, strong selection of E40D/Q was found in these patients, which were at levels similar to those observed at baseline in a recent study [31] , suggesting differential immunological activity in the development of inactive HBsAg-positive carrier status and CHB status: immune activity specifically addressed to minor T-helper epitopes in cases of inactive HBsAg-positive carriers and activity addressed to changes in immunodominant epitopes in CHB. However, this observation must be interpreted with caution because of the small number of inactive HBsAg-positive carriers studied. Lastly, although AA1-11 has been described as a conserved region, some positions showed remarkable variability, particularly codons 3 and 4. The finding that region AA1-11 partially overlaps with the T-helper CD4 + epitope 1-25 [40] suggests that there might be some immunological pressure against this epitope, especially after ADV treatment.
The most important limitation of this study is the small number of inactive HBsAg carriers included. It was difficult to recruit eligible patients for this group because their low viral loads made HBV core analysis impossible. Another limitation involves the analysis of HBV evolution by using direct sequencing techniques, rather than more sensitive methods, such as clonal analysis. Nonetheless, the significant results obtained can be used as the basis for designing a clonal study with ultradeep pyrosequencing methods focused on the most significant regions. It would be of particular interest to perform studies directed to specific positions, such as E64D-N67T, L84D (associated with IFN treatment) or to the highly polymorphic positions 74, 77 and 84.
In conclusion, this study reports that immunodominant regions Th50-69 and B74-84, as well as certain specific AA substitutions appear to be predominantly involved in natural and antiviral therapy-induced evolution in the HBV core protein. More changes occurred under the immune-stimulating effect of IFN than in treatment-free periods or during nucleoside/nucleotide analogue therapies. Some immune-stimulating activity, likely related to maintenance of viral protein synthesis, was associated with nucleoside/nucleotide analogues. This activity was mainly evident in the minor Th28-47 epitope, as was seen in inactive HBsAg-positive carriers.
